Synthesis Capital

Synthesis Capital is a healthcare venture capital firm focused on investments in the biotechnology, pharmaceutical, medical device and healthcare services industries. Founded by a team of accomplished healthcare investment professionals, the firm is a spin out from the private equity firm, Advent International.

Our Portfolio

Recent News

• Aegerion Pharmaceuticals Prices Public Offering of Common Stock
• Amgen to Acquire deCODE Genetics, a Global Leader in Human Genetics
• MedVantx and McKesson Medical-Surgical Announce Co-Promotion Agreement
• Trident Pharmaceuticals Announces Initiation of Phase 1a Clinical Study of HF1020
• Achillion Reports Interim Results on ACH-3102
• Exelixis Announces COMETRIQ™ (cabozantinib) Is Now Available in the U.S.
• Cellzome: GlaxoSmithKline to fully acquire Cellzome for £61 million
• Cubist to Appoint Tom DesRosier as Senior VP, CLO and Secretary
• Enanta Files Registration Statement for Proposed IPO